RS67606B1 - Modifikovani lipidovani peptidi b-lanca relaksina i njihova terapeutska upotreba - Google Patents

Modifikovani lipidovani peptidi b-lanca relaksina i njihova terapeutska upotreba

Info

Publication number
RS67606B1
RS67606B1 RS20260005A RSP20260005A RS67606B1 RS 67606 B1 RS67606 B1 RS 67606B1 RS 20260005 A RS20260005 A RS 20260005A RS P20260005 A RSP20260005 A RS P20260005A RS 67606 B1 RS67606 B1 RS 67606B1
Authority
RS
Serbia
Prior art keywords
peptide
group
lysine
amino acid
acid
Prior art date
Application number
RS20260005A
Other languages
English (en)
Serbian (sr)
Inventor
Olivier Duclos
Stéphane Illiano
Sergio Mallart
Claire Minoletti-Hochepied
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of RS67606B1 publication Critical patent/RS67606B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/64Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20260005A 2018-01-31 2019-01-30 Modifikovani lipidovani peptidi b-lanca relaksina i njihova terapeutska upotreba RS67606B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use
EP19702593.5A EP3746467B1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
RS67606B1 true RS67606B1 (sr) 2026-01-30

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260005A RS67606B1 (sr) 2018-01-31 2019-01-30 Modifikovani lipidovani peptidi b-lanca relaksina i njihova terapeutska upotreba

Country Status (29)

Country Link
US (3) US10961295B2 (enExample)
EP (1) EP3746467B1 (enExample)
JP (1) JP7295871B2 (enExample)
KR (1) KR102755938B1 (enExample)
CN (1) CN111770934B (enExample)
AR (1) AR114325A1 (enExample)
AU (1) AU2019214358B2 (enExample)
BR (1) BR112020014834A2 (enExample)
CA (1) CA3089657A1 (enExample)
CO (1) CO2020008308A2 (enExample)
DK (1) DK3746467T3 (enExample)
ES (1) ES3058633T3 (enExample)
FI (1) FI3746467T3 (enExample)
HR (1) HRP20260016T1 (enExample)
IL (2) IL316406A (enExample)
LT (1) LT3746467T (enExample)
MA (1) MA52994A (enExample)
MX (1) MX2020008096A (enExample)
MY (1) MY199821A (enExample)
NZ (1) NZ766762A (enExample)
PH (1) PH12020551118A1 (enExample)
PL (1) PL3746467T3 (enExample)
PT (1) PT3746467T (enExample)
RS (1) RS67606B1 (enExample)
SG (1) SG11202006903WA (enExample)
SI (1) SI3746467T1 (enExample)
TW (1) TWI763972B (enExample)
UY (1) UY38069A (enExample)
WO (1) WO2019149782A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−2を調製する方法
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
JP6822839B2 (ja) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、及びその組成物
EP3131925B1 (en) 2014-04-17 2020-02-19 The Florey Institute of Neuroscience and Mental Health Modified relaxin b chain peptides
JP2017513875A (ja) * 2014-04-22 2017-06-01 ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 分枝状アミノ酸プローブを有するペプチド類似体
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
NZ766762A (en) 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
AU2022334113A1 (en) * 2021-08-23 2024-03-14 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
PT3746467T (pt) 2026-01-13
JP7295871B2 (ja) 2023-06-21
PL3746467T3 (pl) 2026-04-13
EP3746467B1 (en) 2025-10-08
IL276170B1 (en) 2024-11-01
HRP20260016T1 (hr) 2026-02-27
US20210292387A1 (en) 2021-09-23
JP2021512099A (ja) 2021-05-13
LT3746467T (lt) 2026-01-26
CA3089657A1 (en) 2019-08-08
WO2019149782A1 (en) 2019-08-08
US20240218042A1 (en) 2024-07-04
MY199821A (en) 2023-11-23
CO2020008308A2 (es) 2020-10-30
KR102755938B1 (ko) 2025-01-20
MX2020008096A (es) 2020-09-24
BR112020014834A2 (pt) 2020-12-08
AR114325A1 (es) 2020-08-19
TWI763972B (zh) 2022-05-11
CN111770934B (zh) 2024-10-18
AU2019214358B2 (en) 2023-05-25
MA52994A (fr) 2021-05-05
TW201940505A (zh) 2019-10-16
CN111770934A (zh) 2020-10-13
KR20200116085A (ko) 2020-10-08
US20190233494A1 (en) 2019-08-01
UY38069A (es) 2019-08-30
SG11202006903WA (en) 2020-08-28
IL276170B2 (en) 2025-03-01
EP3746467A1 (en) 2020-12-09
SI3746467T1 (sl) 2026-02-27
IL316406A (en) 2024-12-01
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
PH12020551118A1 (en) 2021-07-05
ES3058633T3 (en) 2026-03-12
US10961295B2 (en) 2021-03-30
AU2019214358A1 (en) 2020-08-20
RU2020126210A (ru) 2022-02-28
IL276170A (en) 2020-09-30
US11725036B2 (en) 2023-08-15
DK3746467T3 (da) 2026-01-12

Similar Documents

Publication Publication Date Title
US11725036B2 (en) Modified lipidated relaxin B chain peptides and their therapeutic use
KR102622642B1 (ko) 인크레틴 유사체 및 그의 용도
US10988523B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
US10988524B2 (en) Modified relaxin B chain peptides and their therapeutic use
EP4482578A1 (en) Crf2 receptor agonists and their use in therapy
AU2024215381A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
RU2804702C2 (ru) Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy